Seeing the Forest for Trevena: $30M, Option for Heart Drug
By Randy Osborne
Thursday, May 9, 2013
revena Inc.'s deal with a subsidiary of Forest Laboratories Inc. brings a $30 million equity investment in exchange for an option to license worldwide rights to TRV027, an angiotensin II Type I receptor biased ligand for acute decompensated heart failure, after results are clear from a 500-patient Phase IIb trial, slated to begin by the end of the year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.